The Park Foundation is focused on increasing awareness about Necrotizing Enterocolitis (NEC). We hope to bridge the gap between community support and scientific intervention to change outcomes in neonates. We are currently focused on raising the remaining funds for Chosen Diagnostics non-invasive NEC diagnostic test, NECDetect, to gain FDA approval. The Park Foundation is working diligently to raise awareness + funds for this work to become a standard of care in hospitals across the country! Please read about NECDetect below.
Chosen Diagnostics receives NICHD award to develop diagnostic test
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health has awarded Chosen Diagnostics a $330K Small Business Technology Transfer Research (STTR) award. The project will focus on the development of a diagnostic biomarker for necrotizing enterocolitis (NEC). NEC is the most common gut inflammatory emergency in preterm infants and is often fatal. As a consequence of limited and poor diagnostic methods available to clinicians, NEC healthcare is the US requires $3 billion annually.